Rocket Pharmaceuticals is a biotechnology company developing gene therapies for rare and devastating diseases. Its pipeline includes programs across hematology, immunology, cardiology, and oncology.
Rocket Pharmaceuticals will participate in two investor conferences in March 2026, with the CEO taking part in a fireside chat and management hosting investor meetings at both events.
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
